H5N1 influenza viruses isolated fromanimals and humans since 2003 separate into distinctclades based on hemagglutinin amino acid sequences.According to the invention, multiple clades are usedin influenza immunization. Thus there is a prime-boostimmunization schedule where a subject receives apriming dose of a first clade of H5 influenza A virusand a boosting dose of a second clade of H5 influenzaA virus. There is also an immunogenic compositioncomprising hemagglutinin antigens from more thanone clade of H5 influenza A virus.